These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Lovastatin and simvastatin--inhibitors of HMG CoA reductase and cholesterol biosynthesis. Alberts AW Cardiology; 1990; 77 Suppl 4():14-21. PubMed ID: 2073667 [TBL] [Abstract][Full Text] [Related]
4. [Efficacy and safety of simvastatin in the treatment of hyperlipidemia in uremic patients undergoing hemodialysis treatment]. Fiorini F; Patrone E; Ardu F; Castelluccio A Minerva Urol Nefrol; 1992; 44(2):165-8. PubMed ID: 1411867 [TBL] [Abstract][Full Text] [Related]
5. Lowering of plasma cholesterol levels in animals by lovastatin and simvastatin. Chao Y; Chen JS; Hunt VM; Kuron GW; Karkas JD; Liou R; Alberts AW Eur J Clin Pharmacol; 1991; 40 Suppl 1():S11-4. PubMed ID: 2044637 [TBL] [Abstract][Full Text] [Related]
6. Comparative effects of simvastatin and lovastatin in patients with hypercholesterolemia. The Simvastatin and Lovastatin Multicenter Study Participants. Farmer JA; Washington LC; Jones PH; Shapiro DR; Gotto AM; Mantell G Clin Ther; 1992; 14(5):708-17. PubMed ID: 1468089 [TBL] [Abstract][Full Text] [Related]
7. [Simvastatin]. Burgmer U; Mohr K Dtsch Med Wochenschr; 1996 Jun; 121(23):769-70. PubMed ID: 8646995 [No Abstract] [Full Text] [Related]
8. An overview: long-term tolerability of lovastatin and simvastatin. Bilheimer DW Zhonghua Yi Xue Za Zhi (Taipei); 1992 Feb; 49(2):138-9. PubMed ID: 1315197 [No Abstract] [Full Text] [Related]
9. Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia. Hsu I; Spinler SA; Johnson NE Ann Pharmacother; 1995; 29(7-8):743-59. PubMed ID: 8520093 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats. Joles J; Willekes-Koolschijn N; Koomans H; Van Tol A; Geelhoed-Mieras T; Crommelin D; Van Bloois L; Krajnc-Franken M; Cohen L; Griffioen M Lab Anim; 1992 Oct; 26(4):269-80. PubMed ID: 1447905 [TBL] [Abstract][Full Text] [Related]
12. [Effects of simvastatin on atherogenic blood lipid pattern]. Alessandri C; Peverini F; Basili S; Barsi R; Paradiso M; Marotta P; Censi C; Cordova C; Balsano F Recenti Prog Med; 1991 Apr; 82(4):225-9. PubMed ID: 1857842 [TBL] [Abstract][Full Text] [Related]
13. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Arnadottir M; Eriksson LO; Thysell H; Karkas JD Nephron; 1993; 65(3):410-3. PubMed ID: 8289991 [TBL] [Abstract][Full Text] [Related]
14. The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolaemia. Eckernäs SA; Roos BE; Kvidal P; Eriksson LO; Block GA; Neafus RP; Haigh JR Br J Clin Pharmacol; 1993 Mar; 35(3):284-9. PubMed ID: 8471404 [TBL] [Abstract][Full Text] [Related]
15. [Effect of the inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-A reductase, pravastatin and simvastatin, on colony formation by hematopoietic progenitor cells]. Kunitama M; Komatsu N; Miura Y Rinsho Ketsueki; 1996 Nov; 37(11):1314-7. PubMed ID: 8960668 [TBL] [Abstract][Full Text] [Related]
16. Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. Nakahara K; Yada T; Kuriyama M; Osame M Biochem Biophys Res Commun; 1994 Aug; 202(3):1579-85. PubMed ID: 8060342 [TBL] [Abstract][Full Text] [Related]
17. Effects of simvastatin, a cholesterol synthesis inhibitor, on phosphatidylcholine synthesis in HepG2 cells. Yanagita T; Yamamoto K; Ishida S; Sonda K; Morito F; Saku K; Sakai T Clin Ther; 1994; 16(2):200-8. PubMed ID: 8062316 [TBL] [Abstract][Full Text] [Related]
18. [Swiss simvastatin multicenter study: 1. Efficacy of 10 mg simvastatin daily in patients with primary hypercholesterolemia]. Riesen WF; Keller U; Del Bufalo A; Reutter FW; Baur HR; Golay A; Bertel O; Kummer H; Kistler H; Ammann F Schweiz Med Wochenschr; 1989 Dec; 119(48):1719-23. PubMed ID: 2694363 [TBL] [Abstract][Full Text] [Related]
19. Statins: 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) reductase inhibitors demonstrate anti-atherosclerotic character due to their antioxidant capacity. Puttananjaiah MK; Dhale MA; Gaonkar V; Keni S Appl Biochem Biotechnol; 2011 Jan; 163(2):215-22. PubMed ID: 20640529 [TBL] [Abstract][Full Text] [Related]
20. Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice. Ajith TA; Harikumar KB; Thasna H; Sabu MC; Babitha NV Clin Chim Acta; 2006 Apr; 366(1-2):322-8. PubMed ID: 16380106 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]